The Medicines Co's revenue for the
three
months ended in Sep. 2019 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.
The Medicines Co's Revenue per Share for the
three
months ended in Sep. 2019 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
The Medicines Co Revenue Historical Data
The historical data trend for The Medicines Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of The Medicines Co's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Medicines Co's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's Revenue distribution charts can be found below:
* The bar in red indicates where The Medicines Co's Revenue falls into.
The Medicines Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Medicines Co (NAS:MDCO) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
The Medicines Co Revenue Related Terms
Thank you for viewing the detailed overview of The Medicines Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
The Medicines Co (The Medicines Co) Business Description
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDCO has been successfully added to your 